HsClpP activator-2

HsClpP activator-2 is an orally active HsClpP agonist with a KD of 40 nM. HsClpP activator-2 potently inhibits SCLC cells including H69 (IC50 = 0.17 μM) and H82 (IC50 = 0.19 μM) . HsClpP activator-2 disrupts mitochondrial membrane potential (MMP), as well as induces apoptosis and ROS in H82 cells. HsClpP activator-2 significantly inhibits tumor growth in non-SMC xenograft models with a tumor growth inhibition. HsClpP activator-2 can be used for the study of small cell lung carcinoma (SCLC) [1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; ClpP; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology

Smiles

O=C(C1=C(C2=CC=C(CO)C=C2)CCN(CC3=CC=CC(C#N)=C3)C1)NCC4=CC=C(C(F)(F)F)C=C4

Molecular Formula

C29H26F3N3O2

Molecular Weight

505.53

References & Citations

[1]Li L, et al. A shape complementarity strategy based on NCA029 enables potent HsClpP agonists for the treatment of small cell lung carcinoma. Eur J Med Chem. 2025 Dec 5;299:118008.